Traws Pharma, Inc. (TRAW) AI-Powered Stock Analysis
See how Traws Pharma, Inc. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
TRAW●NASDAQ
HealthcareBiotechnology
$0.92
$0.35(27.39%)
U.S. Market is Open · 13:13
Advertisement
Traws Pharma, Inc. (TRAW)
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerTraws Pharma, Inc. (TRAW) Stock Overall Grade
Traws Pharma, Inc.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Traws Pharma, Inc.'s overall stock rating.
Forecast
C+Score
51/100Financial Growth
AScore
80/100Fundamental Growth
AScore
83/100Key Ratios
B+Score
70/100Sector Comparison
C+Score
50/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
B+Score
75/100Traws Pharma, Inc. (TRAW) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 51/100 (C+), reflecting weak confidence in its potential. Financial Growth (80/100, A) and Fundamental Growth (83/100, A) highlight its stability, while Key Ratios (70/100, B+) and Sector Comparison (50/100, C+) indicate weak positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), it shows competitive strength. Analyst Consensus (75/100,B+) suggests Low divergence in outlook.Component Analysis Explained
Understand the key factors behind each Traws Pharma, Inc. stock grade, including financials, comparisons, and forecasts.